Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

7.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

746
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
746

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP.

Frontiers in immunology·2026
Same author

Chemotherapy in Combination With Methionine Restriction Induced A Complete Response in a Patient With Recurrent Metastatic Tongue Squamous-Cell Carcinoma.

Cancer diagnosis & prognosis·2026
Same author

Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial-mesenchymal transition via histamine H<sub>1</sub> receptor inverse agonism.

Breast cancer research : BCR·2026
Same author

Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

Scientific reports·2026
Same author

Correction: Tumor <i>Akkermansia muciniphila</i> predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Frontiers in immunology·2026
Same author

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Biomedicines·2025

Related Experiment Video

Updated: Oct 20, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.7K

[Gut Microbiota and Tumor Immune Microenvironment].

Kiyoshi Yoshimura1, Takuya Tsunoda

  • 1Dept. of Clinical Immuno-Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 15, 2021
PubMed
Summary

The gut microbiome influences cancer immunotherapy effectiveness and side effects. Understanding these gut bacteria interactions is key for improving cancer treatments with immune checkpoint inhibitors.

More Related Videos

In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

7.7K
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

9.8K

Related Experiment Videos

Last Updated: Oct 20, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.7K
In Vitro Assay to Study Tumor-macrophage Interaction
08:36

In Vitro Assay to Study Tumor-macrophage Interaction

Published on: August 1, 2019

7.7K
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

9.8K

Area of Science:

  • Oncology
  • Microbiology
  • Immunology

Background:

  • The gut microbiota significantly impacts the tumor microenvironment.
  • Immune checkpoint blockade (ICB) therapy efficacy is influenced by gut microbial composition.
  • Advances in sequencing technologies have accelerated gut microbiota research.

Purpose of the Study:

  • To explore the role of gut microbiota in antitumor responses to ICB.
  • To investigate the association between gut microbiota and adverse events of ICB.
  • To provide insights into optimizing ICB therapy through microbiome modulation.

Main Methods:

  • Analysis of gut microbial composition using next-generation sequencing.
  • Correlation studies between microbial profiles and clinical outcomes (antitumor effects and adverse events).
  • Literature review on current understanding of gut microbiota and ICB.

Main Results:

  • Specific gut bacterial species are associated with positive responses to ICB.
  • Microbiota composition can predict the likelihood and severity of ICB-related adverse events.
  • Gut microbial dysbiosis may contribute to resistance against ICB therapy.

Conclusions:

  • Gut microbiota is a critical factor in cancer immunotherapy.
  • Targeting the gut microbiome holds potential for enhancing ICB efficacy and managing side effects.
  • Further research is needed to elucidate specific microbial mechanisms and develop targeted interventions.